Sleep
-
OSA and the Alzheimer’s continuum
OSA is being increasingly recognized as a potential contributor to neurodegeneration, particularly in the preclinical stages of Alzheimer’s disease. As early intervention becomes a priority in Alzheimer’s prevention, sleep disorders are being investigated as modifiable risk factors.
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
Reexamining treatment for RLS: What do the new AASM guidelines teach us?
The key clinical takeaway from the new guidelines is that dopamine agonists are no longer first-line therapy for RLS, and gabapentinoids should be used as primary therapy for most patients.
-
Early treatment with CPAP may reduce dementia risk for patients with OSA
Sreelatha Naik, MD, FCCP, said the apparent benefit of CPAP therapy is not a surprise; however, more studies are needed to determine if treating sleep apnea can truly mitigate the higher risk of dementia.
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
Novel obesity medications open door to new era in treatment of OSA
In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.
